Scientist announced that a component of the immune system inflammatory cytokine interleukin-18 (IL-18) can prevent, but does not cause, damage to blood vessels behind the retina at the back of eye. This new treatment could be replaceable option for wet age-related macular degeneration (AMD), which can cause central blindness in sufferers. The study was published in the international journal Science Translational Medicine on April 2, 2014.
Sarah Doyle, the first author on the paper from Trinity College Dublin and colleagues took the examination of the role of IL-18 in a mouse model with wet age-related macular degeneration and found surprisingly that low does of IL-18 has no adverse effects on the retina and yet still suppresses abnormal blood vessel growth and directly inhibits vascular endothelial growth factor (VEGF).
Research Assistant Professor in Genetics at Trinity, Matthew Campbell added: “Our findings have highlighted the power of industry-academic collaborations, the results of which should lead to clinical deployment of IL-18 as a treatment for AMD in the short term".
Check the video for more information.
To get the latest news on technology:
Zoomax will launch Snow Pad - the new generation portable video magnifier which can be…
What is omega-3? How does it benefit our eye health and overall health? And where…
In today's fast-paced digital world, where screens have become widespread in our everyday lives, people…
We are delighted to extend a special invitation to you to visit Zoomax Technology at…
Visual challenges take many forms, some causing 20/200 vision while others less detrimental to eye…
For any student, making the most of school opens a gateway to opportunity whether for…
This website uses cookies. If you continue to browse the site, we assume you are fine with how we use cookies on the web.